<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">smp</journal-id><journal-title-group><journal-title xml:lang="ru">Скорая медицинская помощь</journal-title><trans-title-group xml:lang="en"><trans-title>EMERGENCY MEDICAL CARE</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2072-6716</issn><publisher><publisher-name>Northwest State Medical University named after II Mechnikov</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.24884/2072-6716-2016-17-4-76-79</article-id><article-id custom-type="elpub" pub-id-type="custom">smp-175</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОР</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEW</subject></subj-group></article-categories><title-group><article-title>ЭФФЕКТИВНОСТЬ И БЕЗОПАСНОСТЬ СИСТЕМНОГО МЕДИКАМЕНТОЗНОГО ТРОМБОЛИЗИСА НА ФОНЕ РАЗЛИЧНЫХ СХЕМ АНТИАГРЕГАНТНОЙ ТЕРАПИИ У БОЛЬНЫХ С ИНФАРКТОМ МИОКАРДА С ПОДЪЕМОМ СЕГМЕНТА ST</article-title><trans-title-group xml:lang="en"><trans-title>THE EFFICACY AND SAFETY OF SYSTEMIC PHARMACOLOGICAL THROMBOLYSIS IN THE BACKGROUND OF VARIOUS SCHEMES OF ANTIPLATELET THERAPY IN PATIENTS WITH IN MYOCARDIAL INFARCTION WITH ST-SEGMENT ELEVATION</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Юневич</surname><given-names>Д. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Yunevich</surname><given-names>D. S.</given-names></name></name-alternatives><email xlink:type="simple">YunevichDen@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Аксентьев</surname><given-names>С. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Aksentiev</surname><given-names>S. B.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Васюшкина</surname><given-names>К. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Vasyushkina</surname><given-names>K. I.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Родионова</surname><given-names>А. К.</given-names></name><name name-style="western" xml:lang="en"><surname>Rodionova</surname><given-names>A. K.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бельских</surname><given-names>Э. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Belyskih</surname><given-names>E. S.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Областная клиническая больница</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Regional clinical hospital</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Рязанский государственный медицинский университет им. акад. И.П. Павлова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Ryazan State Medical University named after akad. I.P. Pavlov</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>23</day><month>12</month><year>2016</year></pub-date><volume>17</volume><issue>4</issue><fpage>76</fpage><lpage>79</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Юневич Д.С., Аксентьев С.Б., Васюшкина К.И., Родионова А.К., Бельских Э.С., 2016</copyright-statement><copyright-year>2016</copyright-year><copyright-holder xml:lang="ru">Юневич Д.С., Аксентьев С.Б., Васюшкина К.И., Родионова А.К., Бельских Э.С.</copyright-holder><copyright-holder xml:lang="en">Yunevich D.S., Aksentiev S.B., Vasyushkina K.I., Rodionova A.K., Belyskih E.S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://smp.spb.ru/jour/article/view/175">https://smp.spb.ru/jour/article/view/175</self-uri><abstract><p>Исследование тромболитической терапии и сопутствующего антиагрегантного лечения при инфаркте миокарда с подъемом сегмента ST на ЭКГ остается весьма актуальной проблемой. В статье представлен анализ эффективности и безопасности тромболизиса на фоне назначения тикагрелора в течение первых 24 ч. В сравнении с клопидогрелем в составе антитромбоцитарной терапии прием тикагрелора сопровождался достоверным снижением частоты реперфузионных аритмий.</p></abstract><trans-abstract xml:lang="en"><p>Study of thrombolytic therapy and concomitant antiplatelet treatment in myocardial infarction with ST-segment elevation stay a very actual problem. The article presents the analysis of the effecacy and safety of thrombolysis in the background of ticagrelor during the first 24 h. Ticagrelor intake were accompanied by a significant reduction in the frequency of reperfusion arrhythmias in comparison with clopidogrel in the composition of antiplatelet therapy.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>инфаркт миокарда</kwd><kwd>тромболитическая терапия</kwd><kwd>тикагрелор</kwd><kwd>myocardial infarction</kwd><kwd>thrombolytic therapy</kwd><kwd>ticagrelor</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Диагностика и лечение больных острым инфарктом миокарда с подъемом сегмента ST электрокардиограммы. Клинические рекомендации / Рабочая группа по подготовке текста рекомендаций, председатель проф. М.Я. Руда. - М.: Министерство здравоохранения РФ, 2013. - 162 с.</mixed-citation><mixed-citation xml:lang="en">Диагностика и лечение больных острым инфарктом миокарда с подъемом сегмента ST электрокардиограммы. Клинические рекомендации / Рабочая группа по подготовке текста рекомендаций, председатель проф. М.Я. Руда. - М.: Министерство здравоохранения РФ, 2013. - 162 с.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Cannon С.Р., Harrington R.A., James S. et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study // Lancet. - 2010. - Vol. 375. - P. 283-293.</mixed-citation><mixed-citation xml:lang="en">Cannon С.Р., Harrington R.A., James S. et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study // Lancet. - 2010. - Vol. 375. - P. 283-293.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Steg G., James S.K., Altar D. et al. ESC guidelines for the management of infarction in patients presenting with ST-segment elevation // Eur. Heart J. - 2012. - Vol. 33, № 20. - P. 2569-2619.</mixed-citation><mixed-citation xml:lang="en">Steg G., James S.K., Altar D. et al. ESC guidelines for the management of infarction in patients presenting with ST-segment elevation // Eur. Heart J. - 2012. - Vol. 33, № 20. - P. 2569-2619.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Goudevenos J., Ntalas I., Xanthopoulou I. et al. Use of ticagrelor in patients with ST-elevation myocardial infarction undergoing thrombolysis // J. Thromb Thrombolysis. - 2014. - Vol. 37. - P. 356-357.</mixed-citation><mixed-citation xml:lang="en">Goudevenos J., Ntalas I., Xanthopoulou I. et al. Use of ticagrelor in patients with ST-elevation myocardial infarction undergoing thrombolysis // J. Thromb Thrombolysis. - 2014. - Vol. 37. - P. 356-357.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Починка И.Г., Ботова С.Н., Стронгин Л.Г. и др. Описание серии случаев использования тикагрелора при проведении фибринолитической терапии инфаркта миокарда с элевацией сегмента ST // Consilium Medicum. - 2015. - № 17 (10). - С. 43-44.</mixed-citation><mixed-citation xml:lang="en">Починка И.Г., Ботова С.Н., Стронгин Л.Г. и др. Описание серии случаев использования тикагрелора при проведении фибринолитической терапии инфаркта миокарда с элевацией сегмента ST // Consilium Medicum. - 2015. - № 17 (10). - С. 43-44.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
